



1FW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: De Strooper et al.

Serial No.: 10/662,651

Filed: September 15, 2003

For: BINDING DOMAINS BETWEEN
PRESENILINS AND THEIR SUBSTRATES
AS TARGETS FOR DRUG SCREENING

Confirmation No.: 2464

Examiner: G. Emch

Group Art Unit: 1649

Attorney Docket No.: 2676-6086US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

January 17, 2006
Date

Signature

Denise Dyer
Name (Type/Print)

COMMUNICATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a certified copy of Priority Document 01201012.3 EP filed March 16, 2001 for the above referenced application.

Respectfully submitted,

Allen C. Turner
Registration No. 33,041
Attorney for Applicant(s)
TRASKBRITT
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: January 17, 2006
ACT/dd

THIS PAGE BLANK (uspto)



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

01201015.3

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

DEN HAAG, DEN
THE HAGUE, 02/12/05
LA HAYE, LE

This Page Blank (uspto)



Anmeldung Nr:
Application no.: 01201015.3
Demande no:

Anmeldetag:
Date of filing: 16.03.01
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Vlaams Interuniversitair Instituut voor
Biotechnologie vzw.
Rijvisschestraat 120
9052 Zwijnaarde
BELGIQUE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

Binding domains between presenilins and their substrates as targets for drug
screening

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

/00.00.00/

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C07K14/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Binding domains between presenilins and their substrates as targets for drug screening

5 Field of the invention

The present invention relates to the identification of the molecular binding domains between presenilins and its substrates such as amyloid precursor protein and telencephalin. These binding domains can be efficiently used in drug screening assays
10 to screen for compounds capable of modulating the interaction between presenilins and type I transmembrane proteins. The invention further relates to compounds capable of modulating said interaction.

Background to the invention

15

Presenilin 1 and 2 (PS1 and PS2) are highly homologous proteins implicated in familial Alzheimer's disease (FAD) (Rogaev et al., 1995; Sherrington et al., 1995). All FAD-mutations in the presenilins (PSs) increase the secretion of the highly amyloidogenic A β 42 peptide, a major constituent of the plaques in the brains of AD patients (Citron et al., 1997; Duff et al., 1996; Scheuner et al., 1996). A β 42- and the more abundant A β 40-peptide are generated from the larger amyloid precursor protein (APP) by the consecutive action of two enzymes, β - and γ -secretases (De Strooper and Annaert, 2000; Haass and Selkoe, 1993; Selkoe, 1998). Several lines of evidence imply the PSs in γ -secretase activity. (i) A β secretion in cell lines and neurons derived from
20 PS1-/- or PS1-/-PS2-/- embryos is strongly inhibited while the α - and β -cleaved APP C-terminal stubs, the immediate substrates for γ -secretase, accumulate in these cells (De Strooper et al., 1998; Herreman et al., 2000; Naruse et al., 1998; Zhang et al., 2000). (ii) PSs are part of a multiprotein complex that exhibits γ -secretase activity in detergent extracts (Li et al., 2000). (iii) Indirect evidence implies two conserved
25 aspartic acid residues of the transmembrane domains 6 and 7 in the catalytic activity of the γ -secretase (Wolfe et al., 1999). This putative active site displays remote similarity with the catalytic site of the bacterial type-4 prepilin peptidases (Steiner et al., 2000).
30

(iv) Potent γ -secretase inhibitors designed to act as transition state analogues bind PSs (Esler et al., 2000; Li et al., 2000).

PSs are also required for the regulated intramembrane proteolysis of the Notch proteins (De Strooper et al., 1999; Struhl and Greenwald, 1999), thereby acting as molecular switches between proteolysis and cell signaling (Annaert and De Strooper, 1999; Brown et al., 2000). While the absolute requirement of PS for γ -secretase processing is thus clearly established, several observations indicate that a "PS is γ -secretase" hypothesis is probably too simplistic. PSs are for instance integrated into a multiprotein complex (Capell et al., 1998; Verdile et al., 2000; Yu et al., 1998) and one of its components, nicastrin, is apparently involved in the regulation of its proteolytic activity (Yu et al., 2000). Other observations also indicate that the exact role of PS in γ -secretase activity needs further scrutiny. For instance the mutation of Asp257, one of the two aspartates of the putative catalytic site of PS, as well as certain other missense mutations in PS, inhibit Notch but not APP cleavage (Capell et al., 2000; Kulic et al., 2000). This is difficult to conciliate with the idea that the two aspartates constitute the active site of a single protease. Another paradox that needs further work is the discrepancy between the subcellular distribution of PSs and the sites where γ -secretase cleavage of APP or Notch is supposed to occur ('the spatial paradox': Annaert and De Strooper, 1999; Annaert et al., 1999). The complexity of the issues involved is illustrated by studies that demonstrate the role of PS in the Wnt/ β -catenin signaling pathway. Several authors found that PS can bind proteins of the armadillo family. PS1 indirectly modulates Wnt signaling by stabilizing β -catenin (De Strooper and Annaert, 2001; Kang et al., 1999; Nishimura et al., 1999; Soriano et al., 2001; Zhang et al., 1998). As β -catenin binding to PS1 is independent of γ -secretase function (Saura et al., 2000) it follows that PS1 contains several functional domains, and regulates at least more than one signaling pathway. The exact molecular domains involved in the interaction between presenilin and its substrates are not known. In the current invention we have identified that presenilin is binding in a complex two-part to type I transmembrane regions. These novel binding regions are important targets for drug development for the modulation of presenilin mediated intramembrane cleavage and can be used for example for drug development in the fight against Alzheimer's disease. It has been shown in the art that presenilins are endoproteolysed yielding saturable and stable complexes of N-terminal and C-terminal fragments (NTF and CTF)(Thinakaran et al., 1996) (Thinakaran et al., 1997) and that the integrity of PS

including intramolecular interactions between both fragments, is required for its normal biological function (Saura et al., 1999; Tomita et al., 1998). It has also been shown that co-immunoprecipitation of Notch with the PS1-NTF as well as with the PS1-CTF can occur (Ray et al., 1999), although the exact binding sites were not identified.

5 Furthermore mutational analysis has demonstrated that the C-terminus of PS is needed for the stabilization, endoproteolysis and A β 42 overproduction caused by FAD-linked mutations (Thinakaran et al., 1997; Tomita et al., 1999).

Figure Legends

Figure 1: TLN binds PS1 in vitro.

A. Schematic drawing of the domain structure of TLN including the nine Ig-like domains (I to IX). The protein fragment identified by 2-hybrid screening is displayed (TLN/256C). The epitope recognized by antibody B36.1 is indicated. SS=disulfide bridge.

B. Both PS1 and PS2 bind endogenous TLN. Equal amounts of GST-PS1/39C and GST-PS2/39C fusion proteins, or GST alone were incubated with low salt brain extracts. Bound material was separated in 12% SDS-PAGE, blotted and probed with anti-TLN pab B36.1 (1/10,000).

C. The interaction of TLN with PS1/39C is salt-dependent. Triton X100 brain extracts were incubated with equal amounts of immobilized GST-PS1/39C in the presence of increasing salt concentrations. The bound material was analyzed as in B.

D. The PS1-TLN interaction is specific. GST-PS1/39C or GST alone was incubated with (+) or without (-) brain extracts at low (75mM) or high (400mM) salt concentration. The bound material ('beads') was analyzed as above by western blotting using the antibodies indicated. Endogenous TLN was specifically retained on the immobilized GST-PS1/39C especially at 75 mM NaCl. Under those conditions binding was quantitative as deduced from the absence of TLN signals in the unbound supernatant (sup, lane indicated with 75mM, 1/3 of the input material). Other proteins such as synaptophysin, syntaxin or synaptobrevin II, or ER-specific proteins such as calnexin and PDI, did not interact. At long exposure times, a weak signal for endogenous APP could be demonstrated in the bound fractions.

E. Interaction of GST-TLN/256C with endogenous PS1. Immobilized GST-TLN/256C (see A) was incubated with 1% Triton-X100 or 2% CHAPS extracts of mouse brain in the presence of the indicated salt concentrations. GST alone was used as a negative control. PS1-CTF was predominantly detected in the bound fraction of low salt 1% Triton-X100 brain extracts. When extracted with 2% CHAPS both the PS1-NTF and PS1-CTF were bound to GST-TLN/256C. The difference between the intensity of the bands is due to different affinities of the pabs as shown for the crude extract ('Total' in first lane). Binding was largely abolished at high salt concentrations (400mM). No binding was observed in the absence of extract or with GST-beads. Endogenous APP was found to bind as well and the relative amount of bound APP increased in 2% CHAPS brain extracts. No binding was observed with other proteins such as BAP31, synaptobrevin II and ductin.

Figure 2: PS1/39C binds to the transmembrane domain of TLN.

15

A. N- or C-terminal truncated mutants of TLN/256C were generated by *in vitro* transcription/translation and assayed for binding to GST, GST-PS1/39C or GST-PS1/1-81N (PS1 N-terminus fused to GST).

B. Coomassie staining of the different fusion proteins used in the binding reaction. Similar amounts of immobilized fusion proteins were used.

C. Total: autoradiogram of the translated, [³⁵S]-methionine labeled TLN constructs used for the binding reaction. Similar amounts of input material are used. Note the tendency of the intracellular domain (IC) to oligomerize. Only TLN/256C, and the TLN mutants that encompass the transmembrane domain (TMR) of TLN bind efficiently to immobilized GST-PS/39C. No binding was observed with GST alone or GST- PS1/1-81N (lower panels in C). EC: ectodomain of TLN/256C.

D. Mapping of the binding domain of TLN.

The top panel shows the different C-terminal truncated TLN mutants generated by *in vitro* transcription/translation. Radiolabeled translated products (Total) were assayed for binding to GST-PS1/39C (third panel), GST- PS1/1-81N (fourth panel) or GST alone (not shown). Binding becomes virtually abolished when the N-terminal 5 amino acids (Val⁸²⁹-Trp⁸³³) of the transmembrane region of TLN are deleted (construct 8 in top panel).

Figure 3. Mapping the PS1-binding domain in APP.

- A. Schematic drawing and expression in neurons of the different APP C-terminal fragments used. These fragments represent the C-terminal proteolytic products generated by β -, α -, and γ 40 secretase cleavage respectively (APP-C99, -C83 and -C59). As the γ 40-cleaved fragment is rapidly degraded in cell culture, three dishes were pooled to obtain sufficient amounts of the recombinant fragment. SP= signal peptide.
- B. Binding of [35 S]-labeled C-terminal APP-stubs to GST-PS1/39C (top) and GST-PS1/1-81N (bottom, control). All secretase cleaved C-terminal fragments interact with GST-PS1/39C. No binding was observed with GST-PS1/1-81N (or with GST, data not shown).
- C. The C-terminal truncated fragments of APP-C99 expressed by *in vitro* transcription/translation are displayed in the top panel. [35 S]-Labeled translation products were incubated with GST-PS1/39C or -PS1/1-81N (control). Binding to GST-PS1/39C is observed with the first four constructs indicating that the cytoplasmic tail of APP is not required for interaction. Deleting the next eleven amino acids located in the C-terminal end of the transmembrane region of APP completely abolished binding.

Figure 4: Delineation of additional binding sites for TLN and APP in PS1.

- A. Schematic representation of the different GST-PS1 fusion proteins that were used. The name of each construct is indicated. Numbers denote the transmembrane regions, arrow points to the cleavage site in PS1.
- B. Triton-X100 brain extracts were incubated with the fusion proteins and the bound material was analyzed by SDS-PAGE and western blotting using the anti-TLN specific antibody B36.1. Strong binding was observed for all constructs that contained either the first transmembrane region of PS1 or the 39 C-terminal amino acids of PS1. Note that some binding was observed with GST-PS1/102-163N indicating that part of the first intraluminal loop domain may weakly contribute to the binding with TLN. No binding was observed with the transferrin receptor (TFR).
- C. APP-C99 expressed in primary cortical neurons was labeled using [35 S]-methionine. Low salt CHAPS-extracts were generated and incubated with the different fusion proteins displayed in (A). APP-C99 was equally expressed in all cultures (top panel)

and interacted quantitatively with exactly the same PS1 fragments as TLN (bottom panel). Similar results were obtained when Triton-X100 was used.

Figure 5: Developmental regulation and kinetics of TLN expression.

5

A. Time-course of TLN protein expression in developing hippocampal neurons. Neurons from PS1^{-/-} and wild-type littermates were grown for 4, 7, 10 and 16 days, fixed, and immunostained for TLN. The ordinate gives the percentage of neurons at each stage expressing TLN. The number of TLN-positive neurons increases more rapidly in PS1^{-/-} compared to wild-type neurons. At day 10 TLN accumulations in PS1^{-/-} neurons emerged, and at day 16 aggregates were identified in one third of the neurons. Such aggregates were never or very rarely seen in wild-type cultures. Four independent experiments were performed and between 500 and 1200 neurons were counted for each time point (mean±SEM is indicated).

15 B-D. Turnover but not transport rate of newly synthesized TLN is altered in PS1^{-/-} neurons.

Wild type and PS1^{-/-} cortical neurons were transduced with SFV-TLN, pulse-labeled for 15 min with [³⁵S]-methionine and chased for the time periods indicated. The immunoprecipitated TLN was treated with EndoH and analyzed by phosphorimaging (B). The first lane displays TLN at 0 min chase without Endo H treatment. Notice the progressive accumulation of an Endo H resistant band, indicating progressive maturation of the sugar chains during traffick through the Golgi apparatus. In (C) a quantitative analysis of the experiment displayed in (B) is shown. No difference was observed between wild type vs. PS1^{-/-} neurons (mean± SEM, n=3).

25 D. The turnover of newly synthesized TLN as deduced from the experiment displayed in (B) demonstrates that in the absence of PS1 the half-life of SFV-expressed TLN is prolonged (mean± S.E.M., n=3).

Aims and detailed description of the invention

30

In the present invention we have identified a novel substrate for presenilin. More specifically, a specific interaction of the type I transmembrane protein telencephalin (TLN) with PS1 and PS2 is found. TLN is a neuron and region specific member of the ICAM subfamily of intercellular adhesion molecules (Hayflick et al., 1998; Yoshihara

and Mori, 1994). It has been shown that TLN promotes dendritic outgrowth (Tamada et al., 1998; Tian et al., 2000) and contributes to long-term potentiation (Nakamura et al., 2001; Sakurai et al., 1998). The analogy with Notch in promoting dendritic branching (Berezovska et al., 1999; Sestan et al., 1999), and the downregulation of TLN in the brains of AD-patients (Hino et al., 1997), motivated us to investigate the PS1-TLN interaction in detail. We have delineated precisely the binding sites in PS1 and TLN, and can extend those investigations towards APP. Our findings can be integrated into a novel binding model for presenilins with type I transmembrane proteins. Two domains at opposing sites in the PS1 sequence are involved in TLN and also in APP binding. Our results therefore indicate that type I integral membrane proteins can bind via their transmembrane domain to a common binding pocket constituted by the carboxyterminal domain and the first integral membrane domain of PS1. We could not demonstrate any binding *in vitro* between APP, nor TLN (or fragments derived thereof) with the hydrophilic N-terminus of PS1. The fact that the binding domains we identified in PS1 are exceptionally well conserved among different species further corroborates our hypothesis that they are of major functional importance. Consistently, only few disease-linked mutations are found in these regions (Cruts and Van Broeckhoven, 1998; see also <http://molgen-www.uia.ac.be/ADMutations>) while some loss-of-function mutations in these domains in the PS homologues of *C.elegans* (Arduengo et al., 1998; Levitan and Greenwald, 1995; Okochi et al., 2000) and *Drosophila* (Lukinova et al., 1999) have been reported. If both domains, as we demonstrate here, comprise together a functional pocket binding the transmembrane regions of TLN and APP, they should be spatially closely juxtaposed to each other. This indicates for a circular or ring-like structure for PS1. Such a model supports recent findings that intramolecular associations between different domains of PS1 as well as cooperative interactions between both fragments are important for the functionality of the PS complex (Saura et al., 1999; Tomita et al., 1998).

The invention provides in one embodiment an isolated complex between presenilin and a type I transmembrane protein characterized by binding domains comprising a) the first transmembrane domain of presenilin, b) the last 8 carboxyterminal amino acids of presenilin and c) the transmembrane domain of said type I transmembrane protein. A presenilin can be either presenilin 1 or presenilin 2. With the term 'complex' here it is meant an interaction between at least two domains of one or more proteins. The interaction between proteins is known in the art and comprises electrostatic and

hydrophobic interactions. Type I transmembrane proteins are also known in the art and said type I transmembrane proteins comprise substrates of presenilins such as amyloid precursor protein (APP), Notch, cadherins such as E-cadherin, Nicastrin, alfa-secretase, beta-secretase, members of the ICAM-protein family such as telencephalin (TLN).

In another embodiment the invention provides a binding domain of an isolated complex between presenilin and a type I transmembrane protein consisting essentially of the first transmembrane domain of presenilin, set forth by SEQ ID NO1 or SEQ ID NO2 and fragments and variants thereof. Said variants include modifications of the amino acid sequence set forth in SEQ ID NO1 or SEQ ID NO2 and longer sequences that include SEQ ID NO1 or SEQ ID NO2. Fragments of SEQ ID NO1 or SEQ ID NO2 are sequences that are derived thereof. Here fragments and variants belong to the present invention as long as they have the capability of binding in the complex.

In yet another embodiment the invention provides a binding domain of an isolated complex between presenilin and a type I transmembrane protein consisting essentially of the last 8 carboxyterminal amino acids of presenilin, set forth by SEQ ID NO3 or SEQ ID NO4 and fragments and variants thereof.

In yet another embodiment the invention provides a binding domain of an isolated complex between presenilin and a type I transmembrane protein consisting essentially of a sequence of APP set forth by SEQ ID NO5 and fragments and variants thereof.

In yet another embodiment the invention provides a binding domain of an isolated complex between presenilin and a type I transmembrane protein consisting essentially of a sequence of TLN set forth by SEQ ID NO6 and fragments and variants thereof.

In a further embodiment the isolated complex between presenilin and a type I transmembrane protein or the separate binding domains between presenilin and a type I transmembrane can be used to identify compounds that modify the interaction between presenilin and type I transmembrane protein. The method comprises the treatment of said complex or said separate binding domains with at least one compound, and the monitoring of the interaction between the presenilin protein and a type I transmembrane protein.

'Compound' means any anorganic or organic compound, including simple or complex inorganic or organic molecules, peptides, peptido-mimetics, proteins, antibodies, carbohydrates, nucleic acids or derivatives thereof.

A compound can modulate the interaction and consequently this means that a compound can have an antagonizing effect (be an antagonist or an activator) on the interaction and disrupt or prevent the interaction or can have an agonizing effect (be an agonist or an inhibitor) on the interaction and can make the interaction stronger.

5 Monitoring comprises the measuring of the effect of the compound on the interaction between presenilin and a type I transmembrane protein. Said monitoring can be done biochemically by purifying the binding domains and measuring the interaction between the binding domains upon treatment with at least one compound. Alternatively, said monitoring can be measured in an assay comprising cellular and cell-free assays. A

10 non-limiting example of such an assay can be the measurement of presenilin mediated transmembrane cleavage such as for example gamma-secretase cleavage of APP. This type of proteolytic processing has been recently called "regulated intramembrane proteolysis" (rip) (Brown et al. (2000) Cell 100, 391). Presenilin 1 is also involved in the proteolytic processing of the transmembrane domain of other proteins like Notch, a

15 signaling protein involved in cell fate decisions (De Strooper et al., 1999, Nature 398, 518), and Irfp, a protein involved in the control of the unfolded protein response (Niwa et al., 1999, Cell 99, 691) and based on this knowledge assays can be developed to monitor the effect of a compound on the interaction between presenilin and Notch or Irfp.

20 In yet another embodiment the invention provides a compound identified by the use of the herein before described method.

In still another embodiment the invention provides a compound comprising SEQ ID NO1 and SEQ ID2 and fragments, variants, peptidomimetics thereof which bind to a type I transmembrane protein. Fragments and variants of SEQ ID NO1 are part of this

25 invention as long as they bind to a type I transmembrane protein that is a substrate for presenilin. Fragments of SEQ ID NO1 are smaller than the amino acid set forth by SEQ ID NO1. Variants include variations in the amino acid composition set forth by SEQ ID NO1 and variants can also be longer sequences including the amino acid sequence of SEQ ID NO1.

30 In yet another embodiment the invention provides a compound comprising SEQ ID NO3 and SEQ ID NO4 and fragments, variants, peptidomimetics thereof which bind to a type I transmembrane protein.

In yet another embodiment the invention provides a compound comprising SEQ ID NO5 and fragments, variants, peptidomimetics thereof which bind to a presenilin.

In yet another embodiment the invention provides a compound comprising SEQ ID NO6 and fragments, variants, peptidomimetics thereof that bind to a presenilin.

The term 'peptido mimetic' means a molecule able to mimic the biological activity of a peptide but is no longer peptidic in chemical nature. By strict definition, a peptidomimetic is a molecule that no longer contains any peptide bonds (that is, amide bonds between amino acids). However, the term peptide mimetic is sometimes used to describe molecules that are no longer completely peptidic in nature, such as pseudo-peptides, semi-peptides and peptoids. Whether completely or partially non-peptide, peptidomimetics according to this invention provide a spatial arrangement of reactive chemical moieties that closely resembles the three-dimensional arrangement of active groups in the peptide on which the peptidomimetic is based. As a result of this similar active-site geometry, the peptidomimetic has effects on biological systems, which are similar to the biological activity of the peptide.

The peptidomimetic of this invention are preferably substantially similar in both three-dimensional shape and biological activity to the peptides set forth above. Substantial similarity means that the geometric relationship of groups in the peptide that react with for example a type I transmembrane protein is preserved. There are clear advantages for using a mimetic of a given peptide rather than the peptide itself, because peptides commonly exhibit two undesirable properties: (1) poor bioavailability; and (2) short duration of action. Peptide mimetics offer an obvious route around these two major obstacles, since the molecules concerned are small enough to be both orally active and have a long duration of action. There are also considerable cost savings and improved patient compliance associated with peptide mimetics, since they can be administered orally compared with parenteral administration for peptides. Furthermore, peptide mimetics are much cheaper to produce than peptides. Finally, there are problems associated with stability, storage and immunoreactivity for peptides that are not experienced with peptide mimetics. The peptides described in the present invention have utility in the development of such small chemical compounds with similar biological activities and therefore with similar therapeutic utilities. The techniques of developing peptidomimetics are conventional. Thus, peptide bonds can be replaced by non-peptide bonds that allow the peptidomimetic to adopt a similar structure, and therefore biological activity, to the original peptide. Further modifications can also be made by replacing chemical groups of the amino acids with other chemical groups of similar structure. The development of peptidomimetics can be aided by

determining the tertiary structure of the original peptide, either free or bound to a substrate, e.g. presenilin or a transmembrane part of a type I transmembrane protein, by NMR spectroscopy, crystallography and/or computer-aided molecular modelling. These techniques aid in the development of novel compositions of higher potency and/or greater bioavailability and/or greater stability than the original peptide (Dean
5 (1994), BioEssays, 16: 683-687; Cohen and Shatzmiller (1993), J. Mol. Graph., 11: 166-173; Wiley and Rich (1993), Med. Res. Rev., 13: 327-384; Moore (1994), Trends Pharmacol. Sci., 15: 124-129; Hruby (1993), Biopolymers, 33: 1073-1082; Bugg et al. (1993), Sci. Am., 269: 92-98, all incorporated herein by reference]. Once a potential
10 peptidomimetic compound is identified, it may be synthesized and assayed using the method described herein to assess its activity. Thus, through use of the methods described above, the present invention provides compounds exhibiting enhanced therapeutic activity in comparison to the peptides described above. The peptidomimetic compounds obtained by the above methods, having the biological
15 activity of the above named peptides and similar three-dimensional structure, are encompassed by this invention. It will be readily apparent to one skilled in the art that a peptidomimetic can be generated from any of the modified peptides described in the previous section or from a peptide bearing more than one of the modifications described from the previous section. It will furthermore be apparent that the
20 peptidomimetics of this invention can be further used for the development of even more potent non-peptidic compounds, in addition to their utility as therapeutic compounds.

In a further embodiment the invention provides a method for the production of a pharmaceutical composition comprising the usage of at least one compound identified
25 via the complex, or binding domains thereof, of the present invention and further more mixing said compound or a derivative or homologue thereof with a pharmaceutically acceptable carrier.

The administration of a gene or compound or a pharmaceutically acceptable salt thereof may be by way of oral, inhaled or parenteral administration. The active
30 compound may be administered alone or preferably formulated as a pharmaceutical composition. A unit dose will normally contain 0.01 to 50 mg for example 0.01 to 10 mg, or 0.05 to 2 mg of compound or a pharmaceutically acceptable salt thereof. Unit doses will normally be administered once or more than once a day, for example 2, 3, or 4 times a day, more usually 1 to 3 times a day, such that the total daily dose is

normally in the range of 0.0001 to 1 mg/kg; thus a suitable total daily dose for a 70 kg adult is 0.01 to 50 mg, for example 0.01 to 10 mg or more usually 0.05 to 10 mg. It is greatly preferred that the compound or a pharmaceutically acceptable salt thereof is administered in the form of a unit-dose composition, such as a unit dose oral, parenteral, or inhaled composition. Such compositions are prepared by admixture and are suitably adapted for oral, inhaled or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories or aerosols. Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well-known methods in the art. Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate. These solid oral compositions may be prepared by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents. Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating. Preferably, compositions for inhalation are presented for administration to the respiratory tract as a snuff or an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in

combination with an inert carrier such as lactose. In such a case the particles of active compound suitably have diameters of less than 50 microns, preferably less than 10 microns, for example between 1 and 5 microns, such as between 2 and 5 microns. A favored inhaled dose will be in the range of 0.05 to 2 mg, for example 0.05 to 0.5 mg, 0.1 to 1 mg or 0.5 to 2 mg. For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The active compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the active compound. Where appropriate, small amounts of bronchodilators for example sympathomimetic amines such as isoprenaline, isoetharine, salbutamol, phenylephrine and ephedrine; xanthine derivatives such as theophylline and aminophylline and corticosteroids such as prednisolone and adrenal stimulants such as ACTH may be included. As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.

In a further embodiment one or more compounds identified in the invention can be used to modulate presenilin mediated processing of type I transmembrane proteins. As an unlimited example of presenilin mediated processing of type I transmembrane proteins is the presenilin-mediated cleavage of amyloid precursor protein, which leads to beta-amyloid production. Therefore the compounds or a combination thereof of the present invention can be used to inhibit the formation of beta-amyloid and are valuable to prevent or treat Alzheimer's disease.

Finally in another embodiment one or more compounds identified in the present invention can be used to modulate turnover of type I transmembrane proteins. Indeed, the data of the present invention, together with previous investigations, put presenilins at the crossroads of several important signaling pathways involving TLN, Notch, APP,

Cadherin and β -catenin/Wnt. However, this invention not only shows a function of presenilins at the level of regulated intramembrane proteolysis but also points towards an additional role of presenilins on the control of the overall turn-over of type I transmembrane proteins that interact with presenilins. In the present invention it is shown that the presenilin controls the turnover of telencephalin. It has been shown that TLN promotes dendritic outgrowth (Tamada et al., 1998; Tian et al., 2000) and contributes to long-term potentiation (Nakamura et al., 2001; Sakurai et al., 1998). Also a downregulation of TLN has been observed in the brains of AD-patients (Hino et al., 1997). Therefore, the present invention provides a way to modulate the turn-over of type I transmembrane proteins such as telencephalin, being a substrate for presenilin. The possibility to interfere is important for the treatment of Alzheimer's disease and/or to modulate memory formation.

Examples

1. TLN interacts with the carboxyterminus of PS1

We screened an unamplified mouse hippocampal two-hybrid library with the C-terminal eight amino acids of PS1 (PS1-C8) as bait. A specifically interacting clone containing a cDNA sequence encoding the 256 C-terminal amino acids of TLN (TLN/256C) was obtained. TLN is a neuron specific type I integral membrane glycoprotein belonging to the subfamily of intercellular cell adhesion molecules (ICAM). It contains nine tandem Ig-like domains in the extracellular domain, the two most distal domains being included in TLN/256C (Fig. 1A). Endogenous TLN could be precipitated from Triton X-100 brain extracts using recombinant GST fusion proteins containing the 39 C-terminal residues of PS1 or PS2 (PS1/39C, Fig. 1B). The binding was salt dependent (Fig. 1C). Maximal binding was observed at 75 mM NaCl. (Annaert et al., 1997). The interaction is specific as demonstrated in Fig. 1D. No or only weak binding to GST-PS1/39C was observed with ER-resident proteins like calnexin and PDI, or transmembrane proteins like syntaxin, synaptobrevin II or synaptophysin. We detected a weak signal for endogenous holo-APP only after long exposure (Fig. 1D). The reciprocal experiment using GST-TLN/256C protein confirmed that endogenous PS1-CTF bound to TLN in a salt dependent way (Fig. 1E). Although the PS1-NTF/CTF is Triton-X100 sensitive, minor amounts of PS1-NTF were also detected in precipitates of Triton-X100-extracted

APP-C99 (β -cleaved stub), APP-C83 (α -cleaved stub) and APP-C59 (the γ 40-cleaved cytoplasmic domain of APP) were expressed in wild-type neuron cultures (Fig. 3A) and tested for interaction with GST-PS1/39C. All three C-terminal APP fragments specifically bound to GST-PS1/39C, but not to GST-fused with the N-terminus of PS1 (Fig.3B). Therefore the PS binding region in APP must be located distally to the γ 40 cleavage site in the transmembrane domain of APP. We generated consequently a series of C-terminal truncated APP-C99 constructs, expressed them using in vitro transcription/translation and analyzed their binding to immobilized GST-PS1/39C as above (Fig.3C). C-terminal truncation up to the transmembrane region of APP did not affect binding to PS1. However, the further removal of eleven amino acids, i.e. up to the γ 42 cleavage site in the transmembrane domain of APP, completely abolished binding of APP to PS1/39C. This hydrophobic region (Thr⁶³⁹-Lys⁶⁴⁹, based on APP695) is therefore essential for binding to PS1. Importantly, this short amino acid stretch encompasses all known FAD-causing mutations that affect directly γ -secretase cleavage of APP.

3. Delineation of the TLN and APP binding domains in PS1.

We noticed in our initial experiments that some PS1-NTF bind to the GST-TLN/256C fusion proteins (Fig. 1E) even in the presence of Triton-X100, i.e. a condition that dissociates the PS1NTF/CTF complex (Capell et al., 1998). This suggests a direct interaction with GST-TLN/256C. To analyze this further different subdomains of PS1 (Fig. 4A) were fused to GST and their ability to bind endogenous TLN from Triton X-100 brain extracts was assessed. Confirming our previous observations, all fusion proteins that contained the C-terminal 39 amino acids of PS1 displayed specific binding to TLN, while deletion of the C-terminus (GST-PS1/169 Δ 39C) abolished binding. We observed however that GST-PS1/1-163N, i.e. the N-terminal fragment including the first two transmembrane regions, was also binding efficiently to TLN from the brain extracts. Removal of the second transmembrane region did not affect binding, while further removal of the first transmembrane domain (GST-PS1/1-81N), abolished the binding. GST-PS1/102-163N containing the first intraluminal domain and transmembrane domain 2 displayed a rather weak interaction with TLN (Fig. 4B), indicating that it may weakly contribute to the interaction with TLN. Thus besides the carboxyterminal domain, also the first transmembrane domain (Val⁸²-Ser¹⁰²) and

membranes. In the presence of 2% CHAPS however, both PS1-NTF and PS1-CTF were recovered on the beads as both fragments remain non-covalently bound under these conditions (Capell et al., 1998). Apparently the binding of the PS complex to GST-TLN/256C in CHAPS is less efficient than the binding of PS1-CTF alone in Triton-X100. Since CHAPS is less denaturing than TX100, it is possible that other proteins of the complex cause steric hindrance under these conditions (Capell et al., 1998). The significance of the weak binding observed with APP is unclear but could reflect the association of APP with PS1 in high molecular weight complexes rather than a direct binding to GST-TLN/256C. Several other controls demonstrate the specificity of the observed binding interaction (Fig 1E).

2. The first five amino acids of the transmembrane domain of TLN are involved in the binding to the C-terminus of PS1.

We generated a series of constructs coding for subdomains of TLN/256C (Fig 2A) to identify the binding domain. These constructs were expressed using in vitro transcription/translation and assayed for binding to GST-PS1/39C (Fig. 2). Only those constructs that contained the transmembrane region of TLN maintained efficient binding with PS1 (Fig. 2C). However, some caution with this conclusion is indicated because the IC domain of TLN, when expressed alone, tended to form oligomers as can be deduced from its lower mobility in SDS-PAGE (Fig. 2C, Total). This could also explain why this domain did not bind to GST-PS1/39C. Therefore, a series of progressively C-terminal truncated fragments of TLN/256C were generated (Fig. 2D). The first seven fragments (Fig 2D) maintained binding, while from fragment 8 on almost no binding was observed anymore. Therefore, deletion of the five N-terminal amino acids in the transmembrane domain of TLN/256C accounts for the major loss of binding. It follows that amino acid residues Val⁸²⁹-Trp⁸³³ in the transmembrane region of TLN are essential for binding to GST-PS1/39C.

The eleven last amino acid residues of the transmembrane domain of APP are involved in binding to the C-terminus of PS1.

Others have shown that APP-C99, the β -cleaved APP fragment and direct substrate for γ -secretase, can bind to PS1 (Verdile et al., 2000; Xia et al., 2000). Based on our findings with TLN, we therefore hypothesized that an analogous sequence in the transmembrane domain of APP could be responsible for the interaction with PS1.

possibly part of the first loop domain of PS1 can bind TLN. We confirmed that also this binding interaction required the five N-terminal amino acids in the transmembrane domain of TLN (data not shown).

Interestingly, APP-C99 expressed in neuronal cultures bound to exact the same fragments as TLN (Fig 4C), corroborating the conclusion that APP and TLN bind to very similar sites in PS1.

4. TLN does not colocalize with PS1 under steady state conditions.

TLN is a glycosylated cell adhesion protein that is exclusively expressed in neurons of the telencephalon (Benson et al., 1998; Yoshihara et al., 1994). We therefore focussed on the analysis of endogenous TLN in differentiated hippocampal neurons cultured *in vitro*. TLN specifically localized to the somatodendritic plasma membrane. The axons, visualized using anti-Tau antibodies remained negative. TLN displayed a typical reticular staining pattern in horizontal sections and a typical focal adhesion pattern when viewed from laterally, in accordance with its role in neurite outgrowth and heterophilic cell-cell interactions (Tamada et al., 1998; Tian et al., 2000; Tian et al., 1997). Surprisingly, little or no colocalization was observed between TLN and PS1, neither in horizontal, nor in vertical sections. Interestingly however, PS1-positive compartments, probably ER (Annaert et al., 1999), tended to closely tether to focal adhesion sites visualized by TLN immunoreactivity.

5. Missorting of TLN in PS1^{-/-} hippocampal neurons.

In order to demonstrate the physiological significance of the TLN-PS1 interaction, we next analyzed the effects of PS1 deficiency on TLN expression and localization in neurons. While PS1^{-/-} embryos die late in embryogenesis (Hartmann et al., 1999; Shen et al., 1997; Wong et al., 1997), their hippocampal region at day E17 is sufficiently developed to allow derivatisation of primary cultures of hippocampal neurons. No major differences were observed between wild type and PS1^{-/-} deficient neurons in terms of neuronal polarization and differentiation although this remains to be studied in more detail. However, TLN immunostaining patterns were markedly affected by PS1 deficiency. Particularly in fully polarized neurons, TLN immunoreactivity accumulated in large aggregates. Stereoscopic reconstitution demonstrated that these aggregates were organized in honeycomb structures near to or at the cell surface. Vertical

sectioning confirmed the localization of the aggregates close to or at the cell membrane. The aggregates could be immunostained with antibodies directed to the N-terminus as well as to the C-terminus of TLN indicating that probably full-length TLN accumulated in these structures. These accumulations were not seen in the dendrites.

- 5 The overall increase in fluorescence intensity indicated finally that more TLN was expressed in the PS1^{-/-} neurons than in wild-type controls.

We next investigated at what subcellular level TLN accumulated in the neurons. The lack of colocalization of TLN aggregates with the nuclear marker Topro-3, the ER marker-BIP, the IC marker ERGIC-53 or the cis-Golgi marker β COP suggested a post-
10 Golgi localization. We then visualized actin filaments using phalloidin. Only in PS1^{-/-} neurons intense clusters of phalloidin staining were observed in the cell body closely associated with the TLN aggregates. This indicated a local distortion of the actin cytoskeleton probably caused by the accumulating TLN as this was never observed in wild-type neurons. Vertical sections further corroborated the close juxtaposition of actin
15 and TLN. At this resolution it cannot be distinguished whether the TLN immunoreactivity reflects gigantic focal adhesion contacts or a distinct membrane-bound compartment. In any event, TLN accumulation in PS1^{-/-} neurons triggers actin filaments to assemble near these sites.

20 6. PS1 regulates the turnover of TLN

TLN is only detected clearly in brain after birth and rises then rapidly to stable levels within the next month (Yoshihara and Mori, 1994). This increase occurs concomitantly with the intense neurite outgrowth and the establishment of synaptic contacts
25 characteristic of the developing brain. This developmental regulation is equally preserved in the hippocampal neuron cultures. As demonstrated before (Dotti et al., 1988; Goslin and Banker, 1991) hippocampal neurons in culture go progressively through 5 stages of development. These stages are characterized by the progressive acquisition of a fully polarized phenotype. Stage 5 neurons display full axonal and
30 dendritic compartmentalization and synapse formation. We found that at day 4 post-plating (reflecting early stage 4 (Dotti et al., 1988)) only a fraction of the wild-type neurons expressed TLN. This number increased rapidly resulting in about 90% TLN-positive neurons at day 15. In PS1^{-/-} cultures in contrast, already a significant 15% of the neurons displayed TLN immunoreactivity at day 4, and the maximum frequency

transmembrane domain and the carboxyterminal 8 amino acids of PS1 or PS2 are used as templates to design inhibitory peptides or peptido-mimetics.

Non-transfected cells or 'scrambled' peptides are used as negative controls. Established γ -secretase inhibitors are used as positive controls.

- 5 At the end of the incubation period, conditioned media and cell extracts are analyzed for total A β or A β 40 and A β 42. A β peptides are assayed by ELISA or SDS/PAGE combined with western blotting using peptide specific antibodies. The screening focuses on compounds that inhibit total A β secretion/production or selectively A β 40 or A β 42.

10

8. Screening for compounds in a cell-free assay.

A vector bearing cDNA, encoding APP-C99, including a his-tag or HA-tag, or fused to GST is transformed into *E. coli* and induced to express the tagged recombinant protein. Alternatively, mutations at the γ -secretase cleavage site associated with FAD are introduced. Recombinant tagged APP-C99 is affinity purified on nickle resin, HA-antibody immobilized on protein A or G Sepharose or on glutathione beads respectively. Bound recombinant APP-C99 is eluted, dialyzed, concentrated and aliquoted prior to use in the cell-free assay.

- 15 20 Fixed amounts of recombinant APP-C99 are mixed with cleared cell extracts (for example extracted with Triton X100, CHAPS, CHAPSO or Nonidet p40) and incubated overnight at 37°C or 4°C. De novo formed A β is monitored by SDS/PAGE combined with western blotting. Specific antibodies are used to distinguish A β 40 from A β 42 peptides.

- 25 The assay is used to test compounds (peptides or peptidomimetics) that are designed to interfere with the binding of PS1 (or PS2) with APP (or TLN). These compounds are mixed with recombinant APP-C99 and cell extracts. The assay can screen for compounds that interfere with A β production through interfering with the interaction of PS1 (or PS2) with APP (or TLN).

30

was already reached at about 10 days (Fig. 5A). From this stage on, TLN-immunoreactive aggregates were detected (7% of the positive cells). At day 16, TLN aggregates were observed in about one third of the PS1^{-/-} neurons while they remained almost absent in wild-type neurons.

- 5 To determine whether the accelerated TLN-expression in PS1^{-/-} neurons is due to an increased transport rate in the secretory pathway, we performed pulse-chase experiments, assessing the rate of glycosylation/maturation using endo H (Fig. 5B-D). Immediately after pulse labeling, all newly synthesized TLN is endo H sensitive (Fig. 5B). With increasing chase time TLN becomes progressively endo H resistant
- 10 indicating transport through the Golgi apparatus. Quantitative analysis of this process (Fig. 5C) did not reveal any differences in the acquirement of endo H resistant glycosylation of TLN in wild type versus PS1^{-/-} neurons. In contrast, when we assessed the turnover rate of TLN, a significant difference between wild type and PS1^{-/-} neurons could be demonstrated. The absence of PS1 significantly delayed the
- 15 degradation of TLN (Fig. 5D).

Since PS1 is involved in the transmembrane proteolysis of APP and Notch, we tested the hypothesis whether TLN is processed by a γ -secretase activity as well. Because proteolytic removal of the ectodomain is believed to be needed before γ -secretase cleavage can occur (Brown et al., 2000; Struhl and Adachi, 2000), and in analogy with

20 the mNotch Δ E construct (De Strooper et al., 1999; Schroeter et al., 1998), we generated a TLN Δ E construct. Expression of this construct in wild type and PS1 knockout neurons did not reveal any PS1-dependent γ -secretase cleaved fragment.

7. Screening for compounds in a cell-based assay

25

Non-neuronal or neuronal cell lines are transiently or stably transfected with cDNA constructs encoding the carboxyterminal 99 aa of APP fused to its own signal peptide to assure proper orientation in the plane of the membrane (APP-C99). Alternative APP-C99 constructs bearing Familial Alzheimer's Disease (FAD) causing mutations

30 located distal to the γ -secretase cleavage site are considered. Cells expressing either of these recombinant proteins are incubated with cell-permeable peptides or peptidomimetics, as described herein, designed to compete for the binding sites of PS1 (or PS2) with type I transmembrane proteins (for instance APP and TLN). The first

Materials and Methods

5 Yeast Two-Hybrid and Vector Construction

Mouse hippocampal mRNA was used to generate a primary lambda library that was converted to a pAD-GAL4 plasmid library by in vivo mass excision (HybriZAP, Stratagene). The sequence coding for the C-terminal eight amino acids of PS1 was cloned into the pBD-GAL4 vector. Yeast was transformed simultaneously with the bait and the library plasmids using the lithium-acetate method (Gietz et al., 1995). His⁺ colonies were restreaked onto selection agar plates and assayed for lacZ gene expression by the β -galactosidase filter lift assay. We isolated a cDNA sequence encoding the C-terminal 256 amino acids of TLN (TLN/256C) (Fig. 1A).

15 Production of Recombinant Proteins

cDNA's encoding TLN/256C, or various N- and C-terminal fragments of PS1 as indicated were subcloned into pGEX4T-1 (Pharmacia Biotech) and transformed in E. coli BL21. GST fusion protein expressed upon induction with 0.1 mM IPTG was released by sonicating the bacteria in Tris-saline buffer (TS, 150 mM NaCl with 10 mM Tris, pH 7.4) containing 100 μ g/ml lysozyme, 5mM DTT, protease inhibitors and 0.5% Sarcosyl (Frangioni and Neel, 1993). Triton X-100 (1% final) was added to the cleared extract and proteins were bound to Glutathione beads (Pharmacia Biotech).

In Vitro transcription-translation

25 cDNAs encoding fragments of TLN as indicated in the text were cloned in pcDNAzeo3.1. The APP-C-terminal fragment (APP-C99) was subcloned into pGEM-T. Gradual carboxyterminal truncations of TLN256C and APP-C99 were generated using 5' -sense PCR primer 40 nucleotides upstream of the T7 promoter and 3'-antisense primers corresponding to the respective ends of the truncation. PCR-purified products
30 were directly used in the coupled transcription-translation reaction (TnT system, Promega) in the presence of [³⁵S]-methionine. The reaction mixture was diluted 40-fold in low salt buffer (LSB: 75 mM NaCl, 10 mM Tris, 1 mM EDTA, pH 7.4) containing 1% Triton X-100 or 2% CHAPS.

9. Screening for compounds that modulate the turnover of type I transmembrane proteins.

Full-length telencephalin (TLN) or APP are stably transfected in a neuronal cell line (examples are Neuro2A, PC12, NT2N, SH-SY5Y, or wild-type and PS-deficient embryonic stem cells that are allowed to acquire a neuronal phenotype). Culture dishes/plates with semi-confluent cell layers are preincubated with cell-permeable peptides or peptido-mimetics (described under I., including negative and positive controls). Next, cells are metabolically ($[^{35}\text{S}]$ -methionine) pulsed (10 to 30 min) and chased for 0 hrs or 3 hrs in the absence of label. At the end of the experiment cells are lysed and radiolabeled TLN (or APP) is immunoprecipitated using specific polyclonal antibodies. Bound radiolabeled proteins are separated by SDS-PAGE and analyzed using phosphorimaging. The ratio of 3 hrs over 0 hrs pulse is a measure for the turnover of the radiolabeled protein. The assay screens for compounds that inhibit or delay the turnover of TLN or APP. As positive controls, TLN (or APP) is transduced in neuronally differentiated PS-deficient embryonic stem cells. This assay, in combination with previous assays monitoring A β production, enables to distinguish different cell biological functions of PS1 or PS2.

10. Screening for compounds that modify the binding of PS1 (or PS2) to type I transmembrane proteins.

Synthetic peptides comprising the first transmembrane domain or the carboxyterminal 8 aa of PS1 or PS2 (or peptides derived from them) are biotinylated and immobilized on the Fc2 surface of a streptavidin-sensor chip. Biotinylated synthetic 'scrambled' peptides are immobilized on the Fc1 surface. The chips are perfused with solubilized recombinant APP-C99 (or derivatives) or with recombinant TLN-256C (the carboxyterminal 256 aa of TLN) in the absence or presence of peptides or peptidomimetics designed to modify the binding of APP-C99 or TLN-256C to the immobilized peptides. Binding is monitored in a BIAcore 2000 instrument (Pharmacia Biosensor) and measured as the difference between Fc2 and Fc1 binding curves. This assay allows high throughput screening of synthetic compounds modifying the interaction of PS1 or PS2 with type I transmembrane proteins.

deglycosylation, beads were eluted with sample buffer and analyzed by SDS-PAGE and phosphorimaging.

Indirect Immunofluorescence Microscopy

- 5 Hippocampal neurons were fixed and processed for double immunofluorescence microscopy as described (Annaert et al., 1999). Alexa488- and Alexa546-conjugated secondary antibodies (1/1000, Molecular Probes) were used for detection. Topro-3 (1/200, Molecular Probes) was added prior to mounting. Immunostaining was captured through a BioRad MRC1024 confocal microscope and final processing was done with
10 Adobe Photoshop 5.2 software (Adobe, CA).

Antibodies

- Rabbit polyclonal antibody (pab) B36.1 against mouse TLN (Fig 1A) was raised against the 18 C-terminal amino acids GAEGGAETPGTAESPADG of mouse TLN
15 coupled to KLH (Pierce). Pab B17.2, B32.1, B19.2 and mab 5.2 against PS1 and B11.7 against the C-terminus of APP have been described (Annaert et al., 1999; De Strooper et al., 1997; De Strooper et al., 1995). Anti-ductin was generated using the peptide antigen MADIKNNPEYSS-KLH. Monoclonal antibodies (mab) against
20 synaptobrevin II (clone 69.1), synaptophysin (clone 7.2) and syntaxin I (clone 78.1) were kind gifts of R. Jahn (MPI-Biophysical Chemistry, Göttingen, DE). Anti-PDI mab was from Stephen Fuller (EMBL, Heidelberg) and anti-TLN mab (TLN-3) from C. Gahmberg (Helsinki, Finland). Pabs against calnexin, BAP31 and ERGIC-53 were provided by A. Helenius (ETH-Zürich, CH), M. Reth (MPI-Immunologie, Freiburg, DE) and J. Saraste (Univ. Bergen, Norway). Mab directed against the ER-marker Bip or the
25 cis-Golgi coat protein β -COP were purchased from Sigma. Mab 22C11 against APP and anti-Tau-1 were from Boehringer.

Brain extracts

Murine cortices were homogenized in 250 mM sucrose containing 10 mM Tris-HCL pH 7.4, 1 mM EDTA (De Strooper et al., 1999). Nuclei and tissue fragments were removed by low speed centrifugation. Microsomal membranes pelleted by high-speed
5 centrifugation (50K rpm, 1hr) were resuspended in LSB containing 1% Triton X-100 or 2% CHAPS. Aliquots (1 mg/ml) of the cleared extracts (55K rpm, 1hr) were incubated overnight (4°C) with immobilized GST fusion proteins. Beads were washed in low salt extraction buffer containing 0.5 % Triton X-100 and bound proteins were analyzed by SDS-PAGE and western blotting.

Viral constructs

The cDNAs encoding the full-length mouse TLN and TLN Δ E, which lacks the complete ectodomain, were cloned into the SmaI site of pSFV-1. The pSFV-APPC99 and pSFV-APPC87 vectors encode the signal peptide in continuity with the β -cleaved or α -
15 cleaved C-terminal fragment of APP (Lichtenthaler et al., 1999). pSFV-APPC59 encodes the C-terminal fragment of APP generated by γ ₄₀-secretase cleavage. Production, harvesting and storage of SFV particles was done as described (Annaert et al., 1999; De Strooper et al., 1995; Olkkonen et al., 1993; Tienari et al., 1996).

Neuronal transduction and metabolic labeling

Primary cultures of murine hippocampal or cortical neurons and transduction of the neurons with recombinant SFV was done as described before (Annaert et al., 1999; De Strooper et al., 1998; De Strooper et al., 1995; Goslin and Banker, 1991). Cells were labeled in medium containing 100 μ Ci/ml [³⁵S]-methionine (NEN) for 4 hrs at
25 37°C. Cultures were washed twice with Dulbecco's PBS, harvested in LSB containing 1% Triton X100 or 2% CHAPS and used for binding studies as indicated above. Samples were separated in NuPAGE 4-12% or 12% gels (Invitrogen). Radiolabeled bands were detected by PhosphorImager (Molecular Dynamics Inc.) and quantified using ImageQuantNT 4.1. For pulse-chase experiments, cells were metabolically
30 labeled for 15 min, briefly washed and chased for the indicated time periods. Cells were extracted and labeled proteins were immunoprecipitated as detailed before (Annaert et al., 1999; De Strooper et al., 1998). After a final rinse in phosphate buffer (100 mM phosphate, pH 5.7), bound proteins were digested with 10 mU endoglycosidase H (endoH, Boehringer) in the same buffer for 18 hrs at 37°C. After

Brown, M. S., Ye, J., Rawson, R. B., and Goldstein, J. L. (2000). Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. *Cell* 100, 391-8.

Capell, A., Grunberg, J., Pesold, B., Diehlmann, A., Citron, M., Nixon, R., Beyreuther, K., Selkoe, D. J., and Haass, C. (1998). The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex. *J Biol Chem* 273, 3205-11.

Capell, A., Steiner, H., Romig, H., Keck, S., Baader, M., Grim, M. G., Baumeister, R., and Haass, C. (2000). Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and notch [In Process Citation]. *Nat Cell Biol* 2, 205-11.

Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-Wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George Hyslop, P., and Selkoe, D. J. (1997). Mutant presenilins of Alzheimer's disease increase production of 42- residue amyloid beta-protein in both transfected cells and transgenic mice [see comments]. *Nat Med* 3, 67-72.

Cruts, M., and Van Broeckhoven, C. (1998). Presenilin mutations in Alzheimer's disease. *Hum Mutat* 11, 183-90.

Culvenor, J. G., Maher, F., Evin, G., Malchiodi-Albedi, F., Cappai, R., Underwood, J. R., Davis, J. B., Karran, E. H., Roberts, G. W., Beyreuther, K., and Masters, C. L. (1997). Alzheimer's disease-associated presenilin 1 in neuronal cells: evidence for localization to the endoplasmic reticulum-Golgi-intermediate compartment. *J Neurosci Res* 49, 719-31.

De Strooper, B., and Annaert, W. (2000). Proteolytic processing and cell biological functions of the amyloid precursor protein [In Process Citation]. *J Cell Sci* 113, 1857-70.

References

Annaert, W., and De Strooper, B. (1999). Presenilins: molecular switches between proteolysis and signal transduction. *Trends Neurosci* 22, 439-443.

5

Annaert, W. G., Becker, B., Kistner, U., Reth, M., and Jahn, R. (1997). Export of cellubrevin from the endoplasmic reticulum is controlled by BAP31. *J Cell Biol* 139, 1397-410.

10

Annaert, W. G., Levesque, L., Craessaerts, K., Dierinck, I., Snellings, G., Westaway, D., StGeorge-Hyslop, P., Cordell, B., Fraser, P., and De Strooper, B. (1999). Presenilin 1 controls gamma-secretase processing of the amyloid precursor protein in pre-golgi compartments of hippocampal neurons. *Journal of Cell Biology* 147, 277-294.

15

Arduengo, P. M., Appleberry, O. K., Chuang, P., and SW, L. H. (1998). The presenilin protein family member SPE-4 localizes to an ER/Golgi derived organelle and is required for proper cytoplasmic partitioning during caenorhabditis elegans spermatogenesis [In Process Citation]. *J Cell Sci* 111, 3645-54.

20

Arii, N., Mizuguchi, M., Mori, K., and Takashima, S. (1999). Development of telencephalin in the human cerebrum. *Microsc Res Tech* 46, 18-23.

Benson, D. L., Yoshihara, Y., and Mori, K. (1998). Polarized distribution and cell type-specific localization of telencephalin, an intercellular adhesion molecule. *J Neurosci*

25

Res 52, 43-53.

Berezovska, O., Frosch, M., McLean, P., Knowles, R., Koo, E., Kang, D., Shen, J., Lu, F. M., Lux, S. E., Tonegawa, S., and Hyman, B. T. (1999). The Alzheimer-related gene presenilin 1 facilitates notch 1 in primary mammalian neurons. *Brain Res Mol Brain*

30

Res 69, 273-80.

Berezovska, O., McLean, P., Knowles, R., Frosch, M., Lu, F. M., Lux, S. E., and Hyman, B. T. (1999). Notch1 inhibits neurite outgrowth in postmitotic primary neurons. *Neuroscience* 93, 433-9.

- De Strooper, B., and Annaert, W. (2001). Where Notch and Wnt signaling meet: the Presenilin hub. *J Cell Biol* 152, F17-F19.
- De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S.,
5 Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., Goate, A., and Kopan, R. (1999). A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain [see comments]. *Nature* 398, 518-22.
- De Strooper, B., Beullens, M., Contreras, B., Levesque, L., Craessaerts, K., Cordell,
10 B., Moechars, D., Bollen, M., Fraser, P., George-Hyslop, P. S., and Van Leuven, F. (1997). Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins. *J Biol Chem* 272, 3590-8.
- De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert,
15 W., Von Figura, K., and Van Leuven, F. (1998). Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein [see comments]. *Nature* 391, 387-90.
- De Strooper, B., Simons, M., Multhaup, G., Van Leuven, F., Beyreuther, K., and Dotti,
20 C. G. (1995). Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. *Embo J* 14, 4932-8.
- Doan, A., Thinakaran, G., Borchelt, D. R., Slunt, H. H., Ratovitsky, T., Podlisny, M.,
25 Selkoe, D. J., Seeger, M., Gandy, S. E., Price, D. L., and Sisodia, S. S. (1996). Protein topology of presenilin 1. *Neuron* 17, 1023-30.
- Dotti, C. G., Sullivan, C. A., and Banker, G. A. (1988). The establishment of polarity by
30 hippocampal neurons in culture. *J Neurosci* 8, 1454-68.
- Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C. M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., Morgan, D., Gordon, M. N., Holcomb, L., Refolo, L., Zenk, B., Hardy, J., and Younkin, S. (1996). Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. *Nature* 383, 710-3.

Esler, W. P., Kimberly, W. T., Ostaszewski, B. L., Diehl, T. S., Moore, C. L., Tsai, J. Y., Rahmati, T., Xia, W., Selkoe, D. J., and Wolfe, M. S. (2000). Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. *Nat Cell Biol* 2, 428-434.

5

Frangioni, J. V., and Neel, B. G. (1993). Solubilization and purification of enzymatically active glutathione S- transferase (pGEX) fusion proteins. *Anal Biochem* 210, 179-87.

10

Georgakopoulos, A., Marambaud, P., Efthimiopoulos, S., Shioi, J., Cui, W., Li, H. C., Schutte, M., Gordon, R., Holstein, G. R., Martinelli, G., Mehta, P., Friedrich, V. L., and Robakis, N. K. (1999). Presenilin-1 forms complexes with the cadherin/catenin cell-cell adhesion system and is recruited to intercellular and synaptic contacts. *Mol Cell* 4, 893-902.

15

Gietz, R. D., Schiestl, R. H., Willems, A. R., and Woods, R. A. (1995). Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure. *Yeast* 11, 355-60.

20

Goslin, K., and Banker, G. (1991). Rat hippocampal neurons in low-density culture. In *Culturing Nerve Cells*, G. Banker and K. Goslin, eds. (Cambridge, MA: MIT Press), pp. 251-281.

25

Guo, Y., Livne-Bar, I., Zhou, L., and Boulianne, G. L. (1999). Drosophila presenilin is required for neuronal differentiation and affects notch subcellular localization and signaling. *J Neurosci* 19, 8435-42.

Haass, C., and De Strooper, B. (1999). The presenilins in Alzheimer's disease--proteolysis holds the key. *Science* 286, 916-9.

30

Haass, C., and Selkoe, D. J. (1993). Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. *Cell* 75, 1039-42.

- Hartmann, D., Strooper, B. D., and Saftig, P. (1999). Presenilin-1 deficiency leads to loss of Cajal-Retzius neurons and cortical dysplasia similar to human type 2 lissencephaly. *Curr Biol* 9, 719-727.
- 5 Hayflick, J. S., Kilgannon, P., and Gallatin, W. M. (1998). The intercellular adhesion molecule (ICAM) family of proteins. New members and novel functions. *Immunol Res* 17, 313-27.
- Herreman, A., Serneels, L., Annaert, W., Collen, D., Schoonjans, L., and De Strooper, B. (2000). Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. *Nat Cell Biol* 2, 461-462.
- 10 Hino, H., Mori, K., Yoshihara, Y., Iseki, E., Akiyama, H., Nishimura, T., Ikeda, K., and Kosaka, K. (1997). Reduction of telencephalin immunoreactivity in the brain of patients with Alzheimer's disease. *Brain Res* 753, 353-7.
- 15 Hubbard, E. J., Wu, G., Kitajewski, J., and Greenwald, I. (1997). sel-10, a negative regulator of lin-12 activity in *Caenorhabditis elegans*, encodes a member of the CDC4 family of proteins. *Genes Dev* 11, 3182-93.
- 20 Kang, D. E., Soriano, S., Frosch, M. P., Collins, T., Naruse, S., Sisodia, S. S., Leibowitz, G., Levine, F., and Koo, E. H. (1999). Presenilin 1 facilitates the constitutive turnover of beta-catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the beta-catenin-signaling pathway. *J Neurosci* 19, 4229-37.
- 25 Kim, S. H., Lah, J. J., Thinakaran, G., Levey, A., and Sisodia, S. S. (2000). Subcellular localization of presenilins: association with a unique membrane pool in cultured cells. *Neurobiol Dis* 7, 99-117.
- 30 Kirschenbaum, F., Hsu, S. C., Cordell, B., and McCarthy, J. V. (2000). Substitution of a GSK-3beta Phosphorylation Site in Presenilin 1 Separates Presenilin Function from beta-Catenin Signaling. *J Biol Chem* 275, 2.

Klopfenstein, D. R., Kappeler, F., and Hauri, H. P. (1998). A novel direct interaction of endoplasmic reticulum with microtubules. *Embo J* 17, 6168-77.

Kopan, R., and Goate, A. (2000). A common enzyme connects notch signaling and
5 Alzheimer's disease. *Genes Dev* 14, 2799-806.

Kulic, L., Walter, J., Multhaup, G., Teplow, D. B., Baumeister, R., Romig, H., Capell, A., Steiner, H., and Haass, C. (2000). Separation of presenilin function in amyloid beta-peptide generation and endoproteolysis of Notch. *Proc Natl Acad Sci U S A* 97, 5913-
10 8.

Levitan, D., and Greenwald, I. (1995). Facilitation of lin-12-mediated signalling by sel-12, a *Caenorhabditis elegans* S182 Alzheimer's disease gene. *Nature* 377, 351-4.

15 Li, X., and Greenwald, I. (1998). Additional evidence for an eight-transmembrane-domain topology for *Caenorhabditis elegans* and human presenilins. *Proc Natl Acad Sci U S A* 95, 7109-14.

Li, X., and Greenwald, I. (1996). Membrane topology of the *C. elegans* SEL-12 presenilin. *Neuron* 17, 1015-21.
20

Li, Y. M., Lai, M. T., Xu, M., Huang, Q., DiMuzio-Mower, J., Sardana, M. K., Shi, X. P., Yin, K. C., Shafer, J. A., and Gardell, S. J. (2000). From the Cover: Presenilin 1 is linked with gamma -secretase activity in the detergent solubilized state. *Proc Natl Acad Sci U S A* 97, 6138-6143.
25

Li, Y. M., Xu, M., Lai, M. T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduvellil, J. G., Register, R. B., Sardana, M. K., Shearman, M. S., Smith, A. L., Shi, X. P., Yin, K. C., Shafer, J. A., and Gardell, S. J. (2000).
30 Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. *Nature* 405, 689-94.

Lichtenthaler, S. F., Wang, R., Grimm, H., Uljon, S. N., Masters, C. L., and Beyreuther, K. (1999). Mechanism of the cleavage specificity of Alzheimer's disease gamma-

secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. *Proc Natl Acad Sci U S A* 96, 3053-3058.

5 Lukinova, N. I., Roussakova, V. V., and Fortini, M. E. (1999). Genetic characterization of cytological region 77A-D harboring the presenilin gene of *Drosophila melanogaster*. *Genetics* 153, 1789-97.

10 Nakamura, K., Manabe, T., Watanabe, M., Mamiya, T., Ichikawa, R., Kiyama, Y., Sanbo, M., Yagi, T., Inoue, Y., Nabeshima, T., Mori, H., and Mishina, M. (2001). Enhancement of hippocampal LTP, reference memory and sensorimotor gating in mutant mice lacking a telencephalon-specific cell adhesion molecule. *Eur J Neurosci* 13, 179-189.

15 Naruse, S., Thinakaran, G., Luo, J. J., Kusiak, J. W., Tomita, T., Iwatsubo, T., Qian, X., Ginty, D. D., Price, D. L., Borchelt, D. R., Wong, P. C., and Sisodia, S. S. (1998). Effects of PS1 deficiency on membrane protein trafficking in neurons. *Neuron* 21, 1213-21.

20 Nishimura, M., Yu, G., Levesque, G., Zhang, D. M., Ruel, L., Chen, F., Milman, P., Holmes, E., Liang, Y., Kawarai, T., Jo, E., Supala, A., Rogaeva, E., Xu, D. M., Janus, C., Levesque, L., Bi, Q., Duthie, M., Rozmahel, R., Mattila, K., Lannfelt, L., Westaway, D., Mount, H. T., Woodgett, J., St George-Hyslop, P., and et al. (1999). Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex [see comments]. *Nat Med* 5, 164-9.

30 Okochi, M., Eimer, S., Bottcher, A., Baumeister, R., Romig, H., Walter, J., Capell, A., Steiner, H., and Haass, C. (2000). A loss of function mutant of the presenilin homologue sel-12 undergoes aberrant endoproteolysis in *Caenorhabditis elegans* and increased A-beta-42 generation in human cells. *J Biol Chem*.

Olkkonen, V. M., Liljestrom, P., Garoff, H., Simons, K., and Dotti, C. G. (1993). Expression of heterologous proteins in cultured rat hippocampal neurons using the Semliki Forest virus vector. *J Neurosci Res* 35, 445-51.

Polakis, P. (2000). Wnt signaling and cancer. *Genes Dev* 14, 1837-51.

Pradier, L., Carpentier, N., Delalonde, L., Clavel, N., Bock, M. D., Buee, L., Mercken,
5 L., Tocque, B., and Czech, C. (1999). Mapping the APP/presenilin (PS) binding
domains: the hydrophilic N-terminus of PS2 is sufficient for interaction with APP and
can displace APP/PS1 interaction. *Neurobiol Dis* 6, 43-55.

Ray, W. J., Yao, M., Nowotny, P., Mumm, J., Zhang, W., Wu, J. Y., Kopan, R., and
10 Goate, A. M. (1999). Evidence for a physical interaction between presenilin and Notch.
Proc Natl Acad Sci U S A 96, 3263-8.

Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi,
H., Lin, C., Holman, K., Tsuda, T., and et al. (1995). Familial Alzheimer's disease in
15 kindreds with missense mutations in a gene on chromosome 1 related to the
Alzheimer's disease type 3 gene. *Nature* 376, 775-8.

Sakurai, E., Hashikawa, T., Yoshihara, Y., Kaneko, S., Satoh, M., and Mori, K. (1998).
Involvement of dendritic adhesion molecule telencephalin in hippocampal long-term
20 potentiation. *Neuroreport* 9, 881-6.

Saura, C. A., Tomita, T., Davenport, F., Harris, C. L., Iwatsubo, T., and Thinakaran, G.
(1999). Evidence that intramolecular associations between presenilin domains are
obligatory for endoproteolytic processing. *J Biol Chem* 274, 13818-23.

25 Saura, C. A., Tomita, T., Soriano, S., Takahashi, M., Leem, J. Y., Honda, T., Koo, E.
H., Iwatsubo, T., and Thinakaran, G. (2000). The nonconserved hydrophilic loop
domain of presenilin (PS) is not required for PS endoproteolysis or enhanced abeta 42
production mediated by familial early onset Alzheimer's disease-linked PS variants. *J*
30 *Biol Chem* 275, 17136-42.

Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D.,
Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, E., Viitanen, M., Peskind, E.,
Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., and

- Younkin, S. (1996). Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease [see comments]. *Nat Med* 2, 864-70.
- 5 Schroeter, E. H., Kisslinger, J. A., and Kopan, R. (1998). Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain [see comments]. *Nature* 393, 382-6.
- Selkoe, D. J. (1998). The cell biology of beta-amyloid precursor protein and presenilin
10 in Alzheimer's disease [In Process Citation]. *Trends Cell Biol* 8, 447-53.
- Sestan, N., Artavanis-Tsakonas, S., and Rakic, P. (1999). Contact-dependent inhibition of cortical neurite growth mediated by notch signaling [see comments]. *Science* 286, 741-6.
- 15 Shen, J., Bronson, R. T., Chen, D. F., Xia, W., Selkoe, D. J., and Tonegawa, S. (1997). Skeletal and CNS defects in Presenilin-1-deficient mice. *Cell* 89, 629-39.
- Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., and et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease [see comments]. *Nature* 375, 754-60.
- 20 Song, W., Nadeau, P., Yuan, M., Yang, X., Shen, J., and Yankner, B. A. (1999). Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. *Proc Natl Acad Sci U S A* 96, 6959-63.
- Soriano, S., Kang, D. E., Fu, M., Pestell, R., Chevallier, N., Zheng, H., and Koo, E. H.
30 (2001). Presenilin 1 negatively regulates beta-catenin/T Cell Factor/Lymphoid Enhancer Factor-1 signaling independently of beta-amyloid precursor protein and Notch processing. *J Cell Biol* 152, 785-794.

Steiner, H., Kostka, M., Romig, H., Basset, G., Pesold, B., Hardy, J., Capell, A., Meyn, L., Grim, M. L., Baumeister, R., Fichteler, K., and Haass, C. (2000). Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases. *Nat Cell Biol* 2, 848-851.

5

Steiner, H., Romig, H., Grim, M. G., Philipp, U., Pesold, B., Citron, M., Baumeister, R., and Haass, C. (1999). The biological and pathological function of the presenilin-1 Deltaexon 9 mutation is independent of its defect to undergo proteolytic processing. *J Biol Chem* 274, 7615-8.

10

Steiner, H., Romig, H., Pesold, B., Philipp, U., Baader, M., Citron, M., Loetscher, H., Jacobsen, H., and Haass, C. (1999). Amyloidogenic function of the Alzheimer's disease-associated presenilin 1 in the absence of endoproteolysis. *Biochemistry* 38, 14600-5.

15

Struhl, G., and Adachi, A. (2000). Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins [In Process Citation]. *Mol Cell* 6, 625-36.

20

Struhl, G., and Greenwald, I. (1999). Presenilin is required for activity and nuclear access of Notch in *Drosophila* [see comments]. *Nature* 398, 522-5.

Struhl, G., and Greenwald, I. (2001). Presenilin-mediated transmembrane cleavage is required for Notch signal transduction in *Drosophila*. *Proc Natl Acad Sci U S A* 98, 229-234.

25

Sugino, H., Yoshihara, Y., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., and Mori, K. (1997). Genomic organization and chromosomal localization of the mouse telencephalin gene, a neuronal member of the ICAM family. *Genomics* 43, 209-15.

30

Tamada, A., Yoshihara, Y., and Mori, K. (1998). Dendrite-associated cell adhesion molecule, telencephalin, promotes neurite outgrowth in mouse embryo. *Neurosci Lett* 240, 163-6.

Thinakaran, G., Borchelt, D. R., Lee, M. K., Slunt, H. H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., Hardy, J., Levey, A. I., Gandy, S. E., Jenkins, N. A., Copeland, N. G., Price, D. L., and Sisodia, S. S. (1996). Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. *Neuron* 17, 181-90.

Thinakaran, G., Harris, C. L., Ratovitski, T., Davenport, F., Slunt, H. H., Price, D. L., Borchelt, D. R., and Sisodia, S. S. (1997). Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. *J Biol Chem* 272, 28415-22.

Tian, L., Kilgannon, P., Yoshihara, Y., Mori, K., Gallatin, W. M., Carpen, O., and Gahmberg, C. G. (2000). Binding of T lymphocytes to hippocampal neurons through ICAM-5 (telencephalin) and characterization of its interaction with the leukocyte integrin CD11a/CD18 [In Process Citation]. *Eur J Immunol* 30, 810-8.

Tian, L., Nyman, H., Kilgannon, P., Yoshihara, Y., Mori, K., Andersson, L. C., Kaukinen, S., Rauvala, H., Gallatin, W. M., and Gahmberg, C. G. (2000). Intercellular adhesion molecule-5 induces dendritic outgrowth by homophilic adhesion. *J Cell Biol* 150, 243-52.

Tian, L., Yoshihara, Y., Mizuno, T., Mori, K., and Gahmberg, C. G. (1997). The neuronal glycoprotein telencephalin is a cellular ligand for the CD11a/CD18 leukocyte integrin. *J Immunol* 158, 928-36.

Tienari, P. J., De Strooper, B., Ikonen, E., Simons, M., Weidemann, A., Czech, C., Hartmann, T., Ida, N., Multhaup, G., Masters, C. L., Van Leuven, F., Beyreuther, K., and Dotti, C. G. (1996). The beta-amyloid domain is essential for axonal sorting of amyloid precursor protein. *Embo J* 15, 5218-29.

Tomita, T., Takikawa, R., Koyama, A., Morohashi, Y., Takasugi, N., Saido, T. C., Maruyama, K., and Iwatsubo, T. (1999). C terminus of presenilin is required for overproduction of amyloidogenic Abeta42 through stabilization and endoproteolysis of presenilin. *J Neurosci* 19, 10627-34.

Tomita, T., Tokuhira, S., Hashimoto, T., Aiba, K., Saido, T. C., Maruyama, K., and Iwatsubo, T. (1998). Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid beta peptides. Inability of truncated forms of PS2 with familial Alzheimer's disease mutation to increase secretion of Abeta42. *J Biol Chem* 273, 21153-60.

Verdile, G., Martins, R. N., Duthie, M., Holmes, E., Hyslop, P. S., and Fraser, P. E. (2000). Inhibiting amyloid precursor protein C-terminal cleavage promotes an interaction with presenilin 1. *J Biol Chem*.

Weidemann, A., Paliga, K., Durrwang, U., Czech, C., Evin, G., Masters, C. L., and Beyreuther, K. (1997). Formation of stable complexes between two Alzheimer's disease gene products: presenilin-2 and beta-amyloid precursor protein. *Nat Med* 3, 328-32.

Wolfe, M. S., Citron, M., Diehl, T. S., Xia, W., Donkor, I. O., and Selkoe, D. J. (1998). A substrate-based difluoro ketone selectively inhibits Alzheimer's gamma-secretase activity. *J Med Chem* 41, 6-9.

Wolfe, M. S., Xia, W., Moore, C. L., Leatherwood, D. D., Ostaszewski, B., Rahmati, T., Donkor, I. O., and Selkoe, D. J. (1999). Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease [In Process Citation]. *Biochemistry* 38, 4720-7.

Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., and Selkoe, D. J. (1999). Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity [see comments]. *Nature* 398, 513-7.

Wong, P. C., Zheng, H., Chen, H., Becher, M. W., Sirinathsinghji, D. J., Trumbauer, M. E., Chen, H. Y., Price, D. L., Van der Ploeg, L. H., and Sisodia, S. S. (1997). Presenilin 1 is required for Notch1 and Dll1 expression in the paraxial mesoderm. *Nature* 387, 288-92.

Wu, G., Hubbard, E. J., Kitajewski, J. K., and Greenwald, I. (1998). Evidence for functional and physical association between *Caenorhabditis elegans* SEL-10, a Cdc4p-related protein, and SEL-12 presenilin. *Proc Natl Acad Sci U S A* 95, 15787-91.

5 Xia, W., Ray, W. J., Ostaszewski, B. L., Rahmati, T., Kimberly, W. T., Wolfe, M. S., Zhang, J., Goate, A. M., and Selkoe, D. J. (2000). Presenilin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid beta -protein generation. *Proc Natl Acad Sci U S A* 97, 9299-9304.

10 Xia, W., Zhang, J., Perez, R., Koo, E. H., and Selkoe, D. J. (1997). Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease. *Proc Natl Acad Sci U S A* 94, 8208-13.

Yoshihara, Y., and Mori, K. (1994). Telencephalin: a neuronal area code molecule?
15 *Neurosci Res* 21, 119-24.

Yoshihara, Y., Oka, S., Nemoto, Y., Watanabe, Y., Nagata, S., Kagamiyama, H., and Mori, K. (1994). An ICAM-related neuronal glycoprotein, telencephalin, with brain segment-specific expression. *Neuron* 12, 541-53.

20 Yu, G., Chen, F., Levesque, G., Nishimura, M., Zhang, D. M., Levesque, L., Rogaeva, E., Xu, D., Liang, Y., Duthie, M., St George-Hyslop, P. H., and Fraser, P. E. (1998). The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin. *J Biol Chem* 273, 16470-5.

25 Yu, G., Nishimura, M., Arawaka, S., Levitan, D., Zhang, L., Tandon, A., Song, Y. Q., Rogaeva, E., Chen, F., Kawarai, T., Supala, A., Levesque, L., Yu, H., Yang, D. S., Holmes, E., Milman, P., Liang, Y., Zhang, D. M., Xu, D. H., Sato, C., Rogaev, E., Smith, M., Janus, C., Zhang, Y., Aebersold, R., Farrer, L. S., Sorbi, S., Bruni, A.,
30 Fraser, P., and St George-Hyslop, P. (2000). Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing [see comments]. *Nature* 407, 48-54.

Zhang, Z., Hartmann, H., Do, V. M., Abramowski, D., Sturchler-Pierrat, C., Staufenbiel, M., Sommer, B., van de Wetering, M., Clevers, H., Saftig, P., De Strooper, B., He, X., and Yankner, B. A. (1998). Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. *Nature* 395, 698-702.

5

Zhang, Z., Nadeau, P., Song, W., Donoviel, D., Yuan, M., Bernstein, A., and Yankner, B. A. (2000). Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1. *Nat Cell Biol* 2, 463-465.

Claims

1. An isolated complex between presenilin and a type I transmembrane protein characterized by binding domains comprising:
 - a) the first transmembrane domain of presenilin,
 - b) the last 8 carboxyterminal amino acids of presenilin and
 - c) the transmembrane domain of said type I transmembrane protein.
2. An isolated complex according to claim 1 wherein said presenilin is presenilin 1 or presenilin 2.
3. An isolated complex according to claim 1 wherein said type I transmembrane domain protein is selected from the group comprising TLN, APP, Notch, E-cadherin and Nicastrin.
4. A binding domain of an isolated complex according to claims 1-3 consisting essentially of the first transmembrane domain of presenilin, set forth by SEQ ID NO1 or SEQ ID NO2 and fragments and variants thereof.
5. A binding domain of an isolated complex according to claims 1-3 consisting essentially of the last 8 carboxyterminal amino acids of presenilin, set forth by SEQ ID NO3 or SEQ ID NO4 and fragments and variants thereof.
6. A binding domain of an isolated complex according to claims 1-3 consisting essentially of a sequence of APP set forth by SEQ ID NO5 and fragments and variants thereof.
7. A binding domain of an isolated complex according to claims 1-3 consisting essentially of a sequence of TLN set forth by SEQ ID NO6 and fragments and variants thereof.
8. Use of a complex according to claims 1-3 or use of the binding domains of said complex according to claims 4-7 to identify compounds that modify the interaction between presenilin and type I transmembrane protein comprising:

9. treating said complex or binding domains of said complex with at least one compound, and
10. monitoring the interaction of the presenilin protein and a type I transmembrane protein.

5

11. A compound identified by the use according to claim 8.

10

12. A compound according to claim 9 comprising SEQ ID NO1, SEQ ID NO2 and fragments, variants, peptidomimetics thereof which bind to a type I transmembrane protein.

15

13. A compound according to claim 9 comprising SEQ ID NO3, SEQ ID NO4 and fragments, variants, peptidomimetics thereof which bind to a type I transmembrane protein.

20

14. A compound according to claim 9 comprising SEQ ID NO5 and fragments, variants, peptidomimetics thereof which bind to a presenilin.
15. A compound according to claim 9 comprising SEQ ID NO6 and fragments, variants, peptidomimetics thereof which bind to a presenilin.

25

16. A method for the production of a pharmaceutical composition comprising the usage of at least one compound according to claims 9-13 and further more mixing said compound identified or a derivative or homologue thereof with a pharmaceutically acceptable carrier.

30


17. Use of one or more compounds according to claims 9-13 to modulate presenilin mediated processing of type I transmembrane proteins.
18. Use of one or more compounds according to claims 9-13 to modulate turnover of type I transmembrane proteins.

Abstract

The present invention relates to the identification of the molecular binding domains between presenilins and its substrates such as amyloid precursor protein and telencephalin. These binding domains can be efficiently used in drug screening assays to screen for compounds capable of modulating the interaction between presenilins and type I transmembrane proteins. The invention further relates to compounds capable of modulating said interaction.


1/5

Fig. 1




2/5

Fig. 2



3/5


Fig. 3




4/5

Fig. 4


A.



B.




C.



5/5

Fig. 5



+32 9 2446610

SEQUENCE LISTING

<110> Vlaams Interuniversitair Instituut voor Biotechnol

<120> Binding domain between presenilins and their substrates
as targets for drug screening

<130> BDS/PSTMR/080

<140>

<141>

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: human
transmembrane region 1 of presenilin 1

<400> 1

Val Ile Met Leu Phe Val Pro Val Thr Leu Cys Met Val Val Val Val
1 5 10 15Ala Thr Ile Lys Ser
20

<210> 2

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: human
transmembrane region 1 of presenilin 2

<400> 2

Val Ile Met Leu Phe Val Pro Val Thr Leu Cys Met Ile Val Val Val
1 5 10 15Ala Thr Ile Lys Ser
20

+32 9 2446610

20

<210> 3

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
carboxy-terminal of human presenilin 1

<400> 3

Leu Ala Phe His Gln Phe Tyr Ile

1

5

<210> 4

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
carboxy-terminal of human presenilin 2

<400> 4

Leu Ala Ser His Gln Leu Tyr Ile

1

5

<210> 5

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: part of
transmembrane region of human APP

<400> 5

Thr Val Ile Val Ile Thr Leu Val Met Leu Lys

1

5

10

<210> 6

<211> 5

<212> PRT

<213> Artificial Sequence

2.

+32 9 2446610

<220>

<223> Description of Artificial Sequence: part of
transmembrane region of telencephalin

<400> 6

Val Ala Gly Pro Trp

1

5

This Page Blank (uspto)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

this page blank (uspto)